SMALL CAP IDEA: Poolbeg Pharma and the oral drug that could unlock cancer immunotherapy’s
Cancer immunotherapy is one of the most important treatment advances in oncology in a generation.
Bispecific antibodies, CAR-T therapies, checkpoint inhibitors: these are drugs that have transformed outcomes for patients with blood cancers who previously had very limited options. The problem is that they come with a serious catch.
Cytokine release syndrome, known as CRS, is an inflammatory overreaction that occurs when the immune system goes into overdrive following treatment. Think of it as the body responding so aggressively to the cancer threat that it starts attacking healthy tissue. In severe cases it causes organ failure and can be fatal.
More broadly, it creates a capacity problem: patients need close monitoring in specialist hospital settings, tying up beds and limiting how widely these drugs can be used.
Some of the world’s biggest cancer treatments induce the side-effect. Tecvayli, J&J’s bispecific antibody for multiple myeloma, triggers CRS in around 72 per cent of patients.
Bispecific antibodies more broadly show incidence rates of between 60 per cent and 80 per cent. CAR-T therapies, where a patient’s own immune cells are engineered to attack cancer, carry similarly high rates, with approved treatments including Breyanzi, Abecma, and Carvykti all requiring intensive post-infusion monitoring.
Even Keytruda, Merck’s blockbuster checkpoint inhibitor that generated around $29 billion in sales last year, has documented CRS cases.
The current treatment after the fact is tocilizumab, an injectable monoclonal antibody, combined with corticosteroids. Neither prevents the problem from arising in the first place.
That is what Poolbeg Pharma is trying to solve.
What the FDA meeting actually means
POLB 001 is an oral therapy designed to prevent CRS before it develops. There is nothing else like it currently approved.
On 26 May, Poolbeg announced positive feedback from the US FDA at a pre-investigational new drug meeting, a formal step in which a company presents its clinical development plans and receives regulatory guidance before officially applying to begin later stage human trials.
The agency’s response was broadly aligned with Poolbeg’s proposed development strategy, including agreement on the primary endpoint for a future phase III trial.
This matters more than it might initially appear. Broad agreement with the FDA at this stage significantly reduces the risk that a company arrives at late-stage development only to find the regulator views the study design differently.
For the larger pharmaceutical companies Poolbeg is already in discussions with, that clarity on the route to market lowers the perceived risk of backing the programme.
Poolbeg also holds FDA Orphan Drug Designation for POLB 001, a status that confers seven years of US market exclusivity after approval, plus fee reductions and access to fast-track pathways.
Recent patent grants in Australia, Canada, and other territories are strengthening the IP position at the same time the regulatory pathway is clarifying.
The partnering angle
For a company of Poolbeg’s size, the model is not to commercialise POLB 001 independently. The plan is to advance the asset to a meaningful clinical inflection point and then license it to a larger pharmaceutical company, capturing an upfront payment, milestone payments tied to clinical and regulatory progress, and royalties on eventual sales.
These deals can be transformative for small-cap biotechs, often delivering multiples of the entire market capitalisation in a single transaction.
The logic of who might be interested is clear. J&J, which is providing Tecvayli for the POLB 001 TOPICAL trial at no cost to Poolbeg, has a direct commercial interest in a drug that reduces the CRS burden on its own product.
Other bispecific antibody and CAR-T developers, including Pfizer, Regeneron, AbbVie, and Roche, face the same problem across their own pipelines.
A licensing deal of meaningful size, even well short of POLB 001’s peak sales potential, would represent a dramatic re-rating for a company currently valued at £58 million.
The valuation question
Poolbeg’s market capitalisation stands at roughly £58 million, with net cash of approximately £7.7 million as at 31 December 2025, giving an enterprise value of around £50 million.
Even accounting for the share’s doubling in the year-to-date, the valuation still looks modest relative to where the company is in its development arc.
Clinical-stage biotechs with a defined regulatory pathway, Orphan Drug Designation, strong preclinical and clinical data, and a credible blockbuster market opportunity typically command considerably more.
At £58 million, Poolbeg is only just crossing the threshold where businesses of this type tend to find a floor. Cavendish carries a target price of 19p, implying upside of around 130 per cent from the current level.
The key near-term catalyst is interim data from the TOPICAL trial, an open-label study testing POLB 001 in approximately 30 multiple myeloma patients receiving bispecific antibody therapy, the aforementioned Tecvayli from J&J.
That data is expected this summer. If the results are supportive, the partnering conversation accelerates. The regulatory foundation built makes that conversation considerably easier to have.
Now the usual cautions apply here. This story can only be reported as presented. Clinical development is uncertain and trial data can disappoint.
POLB 001 has not yet generated human efficacy data in multiple myeloma patients and the TOPICAL interim readout may not support the programme’s assumptions. AIM stocks are illiquid and volatile, and investors can lose money. Always do your own research before making any investment decision.
But for those willing to look past the modest market cap, the gap between what Poolbeg is building and what the market is currently paying for it is striking.
For all the latest mid- and small-cap news, go to www.proactiveinvestors.co.uk
DIY INVESTING PLATFORMS
AJ Bell
AJ Bell
Easy investing and ready-made portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free fund dealing and investment ideas
interactive investor
interactive investor
Flat-fee investing from £4.99 per month
Freetrade
Freetrade
Investing Isa now free on basic plan
Trading 212
Trading 212
Free share dealing and no account fee
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.